Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings

May 17, 2018 - By Mary Anderson

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During 2017 Q4 the big money sentiment increased to 3. That’s change of 2.21, from 2017Q3’s 0.79. 6 investors sold all, 5 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio is positive. 15 increased positions while 18 funds acquired positions. Funds hold 29.10 million shares thus 180.62% more from 2017Q3’s 10.37 million shares.
Bridgeway Capital reported 0.01% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Blackrock invested 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Camber Cap Management Ltd Company holds 0.44% or 1.00M shs. Morgan Stanley reported 0% stake. Palo Alto Invsts holds 0.19% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 500,913 shs. State Bank Of America De invested in 0% or 35 shs. Manufacturers Life Insurance The holds 806 shs or 0% of its capital. Fmr Limited Liability reported 1.71M shs or 0% of all its holdings. 428,100 were reported by First Manhattan. Ecor1 Cap Ltd Liability reported 4.84 million shs or 4.92% of all its holdings. California Employees Retirement Sys holds 0% or 41,000 shs. Deutsche Bank Ag reported 0% stake. Northern Trust Corporation stated it has 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ghost Tree Limited Liability reported 1.06% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers owns 570,861 shs for 0.2% of their capital.

Dicerna Pharmaceuticals, Inc. registered $1.57 million net activity with 1 buying transaction and 4 sales since December 18, 2017. Weissman James B sold 8,965 shs worth $116,545. $2.00 million worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was bought by Bain Capital Life Sciences Investors – LLC on Monday, December 18.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 8 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:DRNA) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. The stock rating was downgraded by H.C. Wainwright to “Neutral” on Friday, March 23. On Wednesday, April 11 the rating was initiated by Cowen & Co with “Buy”. In Monday, February 5 report SunTrust initiated the stock with “Buy” rating. On Tuesday, March 27 the rating was initiated by FBR Capital with “Hold”. On Friday, March 9 Chardan Capital Markets initiated Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) with “Hold” rating. On Friday, March 9 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

DRNA is touching $13.76 during the last trading session, after decreased 0.04%.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 274.53% change in last May 17, 2017. DRNA has also 29,107 shares volume. DRNA outperformed the S&P500 by 262.98%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is valued at $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Currently it has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were posted by Streetinsider.com, Businesswire.com and Benzinga.com. The first one has “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel” as a title and was posted on May 15, 2018. The next is “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update” on May 14, 2018. And last was posted on May 14, 2018, called “Earnings Scheduled For May 14, 2018”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.